MiNK Therapeutics, Inc.
INKT
$10.72
$0.212.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.00% | 1.42% | -19.53% | -38.95% | -41.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -180.50% | 166.22% | -- | -- | -- |
| Total Operating Expenses | 8.92% | -15.65% | -39.23% | -53.00% | -51.49% |
| Operating Income | -8.92% | 15.65% | 39.23% | 53.00% | 51.49% |
| Income Before Tax | -15.85% | 10.34% | 34.03% | 52.69% | 51.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.85% | 10.34% | 34.03% | 52.69% | 51.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.85% | 10.34% | 34.03% | 52.69% | 51.98% |
| EBIT | -8.92% | 15.65% | 39.23% | 53.00% | 51.49% |
| EBITDA | -9.40% | 15.76% | 39.75% | 53.54% | 52.00% |
| EPS Basic | -2.05% | 21.48% | 41.90% | 58.01% | 55.52% |
| Normalized Basic EPS | 2.70% | 25.03% | 44.69% | 58.65% | 55.46% |
| EPS Diluted | -2.05% | 21.48% | 41.90% | 58.01% | 55.70% |
| Normalized Diluted EPS | 2.70% | 25.03% | 44.69% | 58.65% | 55.46% |
| Average Basic Shares Outstanding | 13.17% | 12.06% | 12.59% | 12.88% | 9.79% |
| Average Diluted Shares Outstanding | 13.17% | 12.06% | 12.59% | 12.88% | 9.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |